uji kepekaan obat anti tuberkulosis lini kedua menggunakan bactec mycobacterium growth indicator tubes (mgit) 960

Clicks: 176
ID: 214271
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #27 of 31 articles by views in Cancer management and research

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract

The emergence of Multidrug resistance tuberculosis (MDR TB) is a failure treatment caused by Mycobacterium tuberculosis is real threat for TB control program. Second line drugs were using for person who has MDR TB. The objective of this study was to evaluate the Mycobacterium Growth Indicator Tube (MGIT) 960 System as media for testing of Mycobacterium tuberculosis susceptibility to second line drugs. Levels of high sensitivity and specificity, and time of the testing time is the parameter being assessed. Thirty MDR TB isolates were tested for susceptibility to ofloxacin, amikacin, and kanamycin by MGIT 960, and the result were compared to those obtain with proportion method on Lowenstein Jensen media, considered a reference method. Results for ofloxacin showed sensitivity 100% and specificity 75%, whereas for amikacin sensitivity 96% and specificity 100%; kanamycin sensitivity showed both specificity of 100%. The time required to obtain result was faster compared to the reference method, with an average of 9 days by the MGIT960.

Reference Key
rukminiati2015jurnaluji Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Yuni Rukminiati
Journal Cancer management and research
Year 2015
DOI
10.22435/jki.v2i2.4043.43-47
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.